Option chain shows key data for Mereo BioPharma Group's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mereo BioPharma Group.

Mereo BioPharma Group (NASDAQ:MREO) Stock, Option Chain

Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APLD

BWLP

HSHP

LQDA

MREO

SERV

SHAK

Liquidia, Shake Shack And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

ABLV

ALTS

AMIX

APDN

BFRI

CING

DGLY

FOXA

FUBO

GOVX

NVOS

OSTX

QNCX

SPRC

VRAX

VSME

XPER

ZCAR

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

wall street future ai

Intraday Update

AAPL

AFRM

AVGR

CASY

CLDI

DRCT

ENVX

FEBO

GDHG

GOOG

GOOGL

KITT

MDIA

NOVA

OBLG

ORCL

PETS

RDFN

RETO

SIFY

SMTK

STRM

TCON

THMO

TNXP

UPST

WLGS

WULF

Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group PLC

Mereo BioPharma: Positioned For Potential Breakthroughs

HRTS: Generating Alpha In Obesity Treatment

Mereo BioPharma Group GAAP EPS of -$0.02

Analyst Gil Blum of Needham maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report), retaining the price target of $7.00. Gil...

Mereo Biopharma Group: A Strong Buy on Promising Clinical Data and Robust Financials

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on MREO stock, giving a Buy rating on August 13. Joseph Schwartz has g...

Strong Buy Rating for Mereo Biopharma Amidst Promising Drug Program Developments

New additions to Roth MKM's ADR portfolio for September

Mereo BioPharma - Lazarus-Like Recovery Impresses, But Lack Of Clarity On Potential Approval Timelines

"The Phase 3 program for setrusumab, led by our partners at Ultragenyx, continues to progress according to plan and we look forward to reporting th...

Mereo BioPharma reports Q3 EPS (2c), consensus (2c)

Analyst Gil Blum from Needham maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the price target at $7.00. ...

Mereo Biopharma Group: Anticipated Positive Developments and Strong Financial Position Justify Buy Rating

Mereo Biopharma ( ($MREO) ) has released its Q3 earnings. Here is a breakdown of the information Mereo Biopharma presented to its investors. Mereo ...

Mereo BioPharma: Strong Cash Position Amid Clinical Progress

AMGN

ARGT

ARGX

ATAT

BGNE

BWAY

CNTA

CRESY

CYTK

GGAL

HRTS

LOMA

MOMO

QFIN

RARE

SONY

VNET

VRNA

Earnings

Press Releases

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Financing

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Abivax

Altimmune

AnaptysBio

Annexon

Astria Therapeutics

Celcuity

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

GRAIL

Humacyte

IGM Biosciences

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Opthea Limited - American Depositary Shares

Opthea

Organogenesis Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Sana Biotechnology

Stoke Therapeutics

Savara

Tourmaline Bio

Needham

Cantor Fitzgerald

Leerink Partners

Baird

SVB Leerink

Comments

Mereo BioPharma Group

Mereo BioPharma Group (MREO) Options

Mereo BioPharma Group (NASDAQ:MREO) Stock, Option Chain

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga